Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2019
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2019, provides an overview of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline landscape.
Acute myelocytic leukemia (AML), also known as acute myelogenous leukemia is a type of cancer that affects the blood and the bone marrow. Immature white blood cells accumulate in the bone marrow thus blocking the production of normal blood cells. These cells further enter the blood stream and spread to the other parts of the body. Symptoms for AML include fatigue, fever, bleeding, breathing problems, weight loss. The predisposing factors involved are exposure to radiation or chemicals and smoking. Treatment includes chemotherapy, transfusions, transplant and surgery.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 1, 18, 131, 123, 2, 8, 219, 34 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 16, 18, 3, 1, 43 and 27 molecules, respectively.
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2019
Table of Contents
Introduction
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Overview
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics Development
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Therapeutics Assessment
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Companies Involved in Therapeutics Development
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Drug Profiles
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Dormant Projects
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Discontinued Products
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by 4SC AG, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AB Science SA, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AbbVie Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ABL Bio Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Actinium Pharmaceuticals Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ADC Therapeutics SA, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Adlai Nortye Biopharma Co Ltd, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Advanced BioDesign, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Advenchen Laboratories LLC, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aeglea BioTherapeutics Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Affichem SA, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Agios Pharmaceuticals Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AI Therapeutics, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aileron Therapeutics Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AIMM Therapeutics BV, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aleta Biotherapeutics Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AlfaSigma SpA, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Allogene Therapeutics Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Amgen Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Amphivena Therapeutics Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Amplia Therapeutics Ltd, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Angiocrine Bioscience Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Anhui Anke Biotechnology (Group) Co Ltd, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ANP Technologies Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Antisense Therapeutics Ltd, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AnyGen Co Ltd, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by APIM Therapeutics AS, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aprea Therapeutics AB, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AptaBio Therapeutics Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aptevo Therapeutics Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aptose Biosciences Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aravive Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Arcellx Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Argenx SE, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Arog Pharmaceuticals Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Arrien Pharmaceuticals LLC, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Arvinas Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Ascentage Pharma Group International, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aslan Pharmaceuticals Ltd, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Astellas Pharma Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Astex Pharmaceuticals Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AstraZeneca Plc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Atara Biotherapeutics Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Athenex Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by ATP Biopharm, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AUM Biosciences Pte Ltd, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Auransa Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Aurigene Discovery Technologies Ltd, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AVEO Oncology Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Avidin Ltd, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by AVROBIO Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Avvinity Therapeutics Ltd, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bantam Pharmaceutical LLC, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bayer AG, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by BCI Pharma SA, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Beam Therapeutics Inc, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Beijing Immunochina Medical Science & Technology Co Ltd, H2 2019
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline by Bellicum Pharmaceuticals Inc, H2 2019
List of Figures
Number of Products under Development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Top 10 Routes of Administration, H2 2019
Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
Global Antioxidant Vitamins Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 100
The global Antioxidant Vitamins market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
North American market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Antioxidant Vitamins is estimated to increase from $ million in 2023 to reach $ millio......
Global Clavulanate Potassium Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 86
The global Clavulanate Potassium market was valued at US$ 446.6 million in 2023 and is anticipated to reach US$ 637.2 million by 2030, witnessing a CAGR of 5.2% during The forecast period 2024-2030.
North American market for Clavulanate Potassium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Clavulanate Potassium is estimated to increase from $ million in 2023......
Global Amoxicillin Sodium Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 84
The global Amoxicillin Sodium market was valued at US$ 460.9 million in 2023 and is anticipated to reach US$ 735.1 million by 2030, witnessing a CAGR of 7.0% during The forecast period 2024-2030.
North American market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Amoxicillin Sodium is estimated to increase from $ million in 2023 to reach......
Global Melatonin Supplements Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 106
The global Melatonin Supplements market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
North American market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Melatonin Supplements is estimated to increase from $ million in 2023 to reach $ mil......
Global Sleeping Pills (Prescription Drugs) Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 93
The global Sleeping Pills (Prescription Drugs) market was valued at US$ 1022.3 million in 2023 and is anticipated to reach US$ 1437.8 million by 2030, witnessing a CAGR of 4.9% during The forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical......
Global Sleeping Pills Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 94
The global Sleeping Pills market was valued at US$ 2042.3 million in 2023 and is anticipated to reach US$ 2979.5 million by 2030, witnessing a CAGR of 3.8% during The forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......
Global Zinc Oral Drops Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 85
The global Zinc Oral Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
North American market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Zinc Oral Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a......
Global Zinc Drops Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 85
The global Zinc Drops market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030.
North American market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030.
Asia-Pacific market for Zinc Drops is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % duri......
Global Anti-Infectives Market Research Report 2024
Published: 10-Jan-2024 Price: US 2900 Onwards Pages: 78
The global Anti-Infectives market was valued at US$ 22700 million in 2023 and is anticipated to reach US$ 27480 million by 2030, witnessing a CAGR of 2.3% during The forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estima......
SERVICES
Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
Payment Flexibility
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details -
[email protected] / +1 888 391 5441 )
- Ad Hoc
-
- Pay - as - you - go / Bucket Subscriptions
- Fixed Cost for #of reports
- Customize / Personalize as per your needs
